As biosimilars enter the US market, will they be used, and can they reduce spending?
by Erik D. Smith, Ph.D., and Tom Yang, Ph.D., Deloitte Consulting, LLPLast fall, the Food and Drug Administration (FDA) approved the first biosimilar to treat multiple types of cancer.i While biosimilars have tremendous potential, there also is a good bit of uncertainty around them, particularly in oncology where biologics can have a predominant role in treatment.
February is National Cancer Prevention Month, which gives us a nice opportunity to explore the role biosimilars could play in preventing and treating cancer.
Read more
Subscribe
Subscribe to Blog via Email
This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.
Stay connected